AROTINOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H21N3O2S3
Molecular Weight	371.541
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)CSC1=NC(=CS1)C2=CC=C(S2)C(N)=O

InChI

InChIKey=BHIAIPWSVYSKJS-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S3
Molecular Weight	371.541
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11675958
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/6200619

Arotinolol (INN, marketed under the tradename Almarl) is a medication in the class of mixed alpha/beta blockers. It is used in the treatment of high blood pressure and essential tremor. The recommended dosage is 10–30 mg per day.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adrenergic receptor beta 87 Target ID: CHEMBL2094118 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6200619	Antagonist 2778
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6200619	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11675958	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and beta-adrenergic blocking action of a new thiazolylthiopropanolamine derivative.	1978 Sep	29117
Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes.	2001 Jul	11478592
Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report.	2001 Mar	11325074
A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor.	2003 Aug	12853233
Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase.	2003 Oct	14598329
Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol.	2005 Mar	15734668
Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats.	2009 Dec	19822980
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
Overview of essential tremor.	2010 Sep 7	20856604

Patents

Sample Use Guides

In Vivo Use Guide

10-20 mg twice daily for 4 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:30:24 UTC 2023` Edited by `admin` on `Sat Dec 16 16:30:24 UTC 2023`
Record UNII	394E3P3B99
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AROTINOLOL

Official Name

English

(±)-5-(2-((3-(TERT-BUTYLAMINO)-2-HYDROXYPROPYL)THIO)-4-THIAZOLYL)-2-THIOPHENECARBOXAMIDE

Systematic Name

English

arotinolol [INN]

Common Name

English

AROTINOLOL [MI]

Common Name

English

NSC-317940

Code

English

Arotinolol [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576